Outset Medical (OM) Q3 2024 earnings summary

Executive summary

• Q3 2024 marked a return to sequential growth, with revenue of $28.7 million, strong recurring revenue, and gross margin expansion year-over-year.

• Commercial transformation and restructuring initiatives were largely completed, optimizing the commercial organization and reducing operating expenses.

• Net loss for Q3 2024 was $27.9 million ($0.55/share), a significant improvement from $46.2 million in Q3 2023, driven by cost reduction efforts.

• Gross margin improved to 34.3% in Q3 2024 from 23.6% in Q3 2023, primarily due to a higher mix of consumables and services.

• FDA clearance for TabloCart with Prefiltration in May 2024 allowed resumption of distribution.

Financial highlights

• Q3 revenue was $28.7 million, up 5% sequentially but down 6% year-over-year due to lower console sales.

• Recurring revenue reached an all-time high, with treatment revenue up 14% and service revenue up 22% year-over-year.

• Gross profit for Q3 2024 was $9.8 million, up from $7.2 million in Q3 2023; gross margin rose by 10.7 percentage points to 34.3%.

• Non-GAAP net loss was $20.2 million ($0.39/share), 18% lower sequentially and 43% lower year-over-year.

• Operating expenses declined 15% sequentially and 36% year-over-year to $26.5 million.

• Ended Q3 with $179 million in cash, cash equivalents, short-term investments, and restricted cash.

Outlook and guidance

• Full-year 2024 revenue guidance raised to approximately $112 million from $110 million.

• Non-GAAP gross margin for 2024 expected in the mid-30% range, up from prior low to mid-30% guidance.

• 2024 operating expenses anticipated at roughly $120 million, with a run rate just over $100 million.

• Management expects continued operating losses in the near term as investments are made to support anticipated growth.

• Existing cash, cash equivalents, short-term investments, and debt proceeds are expected to meet needs for at least the next 12 months.